Empagliflozin Reversal of Arterial StiffnEss in Aging

Inclusion Criteria:

* Able to provide consent
* 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)
* Stable anti-hypertensive medication regimen (if in use) for at least 90 days
* Evidence of arterial stiffening (defined as carotid-femoral PWV \>/= 8 m/s) at the time of screening visit.

Exclusion Criteria:

* Diabetes
* BMI\>/= 45kg/m2
* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
* Estimated glomerular filtration rate GFR \< 29 mL/min
* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
* Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
* Use of hormone replacement therapy
* Body weight change ≥10% within the last 6 months
* Uncontrolled hypertension during screening visit (\>180/110 mmHg)
* Symptomatic hypotension and/or a SBP \<100 mmHg
* History of ketoacidosis
* High fall risk per assessment of study physician and/or safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements)
* Anticipated need of prolonged fasting
* History of recurrent UTIs or mycotic genital infections
* Following a low-carbohydrate diet (\<20 grams/day)
* Participation in regular exercise \> 3 days/week per week at a moderate or vigorous intensity
* Known sensitivity to nitrate medications